Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: psoriasis

Complex Treatment: Cancer, Immunotherapy & Rheumatic Disease

Richard Quinn  |  May 6, 2017

Some cancer patients taking immune checkpoint inhibitors experience immune-related adverse events. Laura C. Cappelli, MD, MHS, says rheumatologists are natural partners with oncologists to treat this patient population…

Filed under:ConditionsDrug Updates Tagged with:adverse eventsCancerimmune checkpoint inhibitor (ICI)immune-related adverse eventsimmunotherapy

Institute for Clinical Economic Review Final Report on RA Treatments

Mary Beth Nierengarten  |  May 4, 2017

On April 7, 2017, the Institute for Clinical and Economic Review (ICER) published its final report, titled, Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value.1 The stated objective of the report was to assess the comparative clinical effectiveness of the targeted immune modulators (TIMs) used to treat patients with moderate to severe active rheumatoid…

Filed under:Drug UpdatesPractice SupportProfessional TopicsRheumatoid Arthritis Tagged with:Institute for Clinical and Economic Review (ICER)targeted immune modulators (TIMs)Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value

FDA to Review Immediate-Release Oxycodone; Plus NICE Recommends Secukinumab

Michele B. Kaufman, PharmD, BCGP  |  May 1, 2017

A new formulation of oxycodone in 10 and 15 mg doses is being reviewed by the FDA for treating pain…

Filed under:AnalgesicsBiologics/DMARDsConditionsDrug UpdatesPsoriatic Arthritis Tagged with:FDAFood and Drug AdministrationOpioidsPsoriatic Arthritissecukinumab

EMA Panel Recommends Nod for Sanofi, Regeneron’s Arthritis Drug

Reuters Staff  |  April 24, 2017

(Reuters)—A European Medicines Agency panel said on Friday it recommended granting marketing approval to Sanofi and Regeneron’s experimental drug to treat rheumatoid arthritis (RA). The Committee for Medicinal Products for Human Use gave a positive opinion on the drug, sarilumab (Kevzara), citing its ability to reduce the signs and symptoms of RA. Sarilumab, the active…

Filed under:Drug Updates Tagged with:European Medicines AgencyRheumatoid Arthritis (RA)sarilumab

Intimacy & Rheumatic Conditions

Karen Appold  |  April 14, 2017

The side effects of rheumatic conditions and their treatments can cause symptoms some may find awkward or embarrassing to discuss with their physicians. But Ara Dikranian, MD, says rheumatologists must address intimacy issues, both physical and emotional, with all patients…

Filed under:Conditions Tagged with:intimacylifestylepatient carepatient communicationrelationshipsex

Moderate Alcohol Use Could Be Safe with Methotrexate for RA

Scott Baltic  |  April 13, 2017

NEW YORK (Reuters Health)—In patients taking methotrexate for rheumatoid arthritis (RA), moderate alcohol consumption – that is, no higher than existing U.K. guidelines for the general population – was not associated with an increased risk of transaminitis, researchers say. The study is both the largest to examine alcohol and methotrexate (MTX) and the first to…

Filed under:ConditionsRheumatoid Arthritis Tagged with:Methotrexatemoderate alcohol consumptionMTXRheumatoid Arthritis (RA)transaminitis

Dermatology Consults May Cut Hospital Stays, Readmissions

Marilynn Larkin  |  March 27, 2017

NEW YORK (Reuters Health)—Inpatient dermatology consultations were associated with shorter hospital stays and reduced readmissions in a U.S. medical center and may do the same elsewhere, researchers in Ohio suggest. “A few decades ago, patients with severe psoriasis, drug reactions, blistering diseases and even severe eczema would be admitted to the hospital under close dermatology…

Filed under:ConditionsOther Rheumatic Conditions Tagged with:dermatitisDermatologyPsoriasisskinskin diseaseskin inflammationsystemic lupus erythematosus (SLE)

Cancer Risk for Patients with Juvenile Idiopathic Arthritis Taking TNF Inhibitors

Thomas R. Collins  |  March 20, 2017

WASHINGTON, D.C.—Juvenile idiopathic arthritis (JIA) patients taking TNF inhibitors don’t develop new cancers at a higher rate than JIA patients who don’t take TNF inhibitors, according to the largest study so far conducted to study the possible link. The findings were reported at the 2016 ACR/ARHP Annual Meeting in an abstract session that also included…

Filed under:ConditionsMeeting ReportsResearch Rheum Tagged with:2016 ACR/ARHP Annual MeetingAmerican College of Rheumatology (ACR)CancerinhibitorJuvenile idiopathic arthritisPediatricsrateResearchrheumatologyriskTNFTreatment

Factors that Influence Biologic Therapy Choices for Patients with Rheumatoid Arthritis

Michele B. Kaufman, PharmD, BCGP  |  March 20, 2017

Recent research analyzed factors influencing the selection of the first-line biologic medications and the real-life factors that lead to switching from those medications to other biologics in treating rheumatoid arthritis (RA). The study compared the use of abatacept and tocilizumab with a tumor necrosis factor alpha inhibitor (TNFi).1,2 Participants were enrolled in the Lombardy Rheumatology…

Filed under:ConditionsDrug UpdatesRheumatoid Arthritis Tagged with:biologic therapiesdrugMedicationpatient carephysicianRheumatic DiseaseRheumatoid arthritisrheumatologistrheumatology

Paternal Methotrexate Exposure Not Tied to Adverse Pregnancy Outcomes

Scott Baltic  |  March 19, 2017

NEW YORK (Reuters Health)—A father’s exposure to methotrexate 90 days or less before conception “should not be of major concern,” researchers say. Prepregnancy paternal methotrexate exposure appears to confer no increased risk of major or minor congenital malformation, stillbirth or preterm birth in his offspring, their study found. Methotrexate is a first-line therapy for rheumatoid…

Filed under:Drug Updates Tagged with:birthMethotrexateparenthoodpregnancypreterm birth

  • « Previous Page
  • 1
  • …
  • 34
  • 35
  • 36
  • 37
  • 38
  • …
  • 55
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences